

(±)-2-Hydroxymethyl-pyrrolidine-1-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;
2-Dimethylamino-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;
E-N-(3-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-methanesulfonamide;
Isoxazole-5-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;
1-(1,1-Dimethyl-3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-3-ethyl-urea;
and the pharmaceutically acceptable salts, prodrugs and solvates of the foregoing compounds.

17. Canceled

18. Canceled

19. Canceled

20. Canceled

21. (Original) A pharmaceutical composition for the treatment of abnormal cell growth in a mammal comprising an amount of a compound of claim 1 that is effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier.

REMARKS

Favorable reconsideration and allowance are respectfully requested. Claims 1, 5 to 6, 11 to 16 and 21 are pending. By this amendment, Applicants have deleted certain species that are no longer commensurate with the current scope of claim 1. The Examiner rejected the claims under the judicially created doctrine of obviousness-type double patenting and under 35 U.S.C. § 112, first paragraph. But in a telephonic interview between the undersigned and the Examiner on August 27, 2004, for which the Applicants are grateful, the


Patent Application
Attorney Docket No. PC10760A
U.S. Serial No. 09/883,752

Examiner indicated that if the offending species were canceled from claim 16, the claims would be in condition for allowance. Therefore, in the interests of advancing prosecution on the merits, Applicants have amended the claim as suggested by the Examiner.

In view of the foregoing remarks and amendments, Applicants submit that the claims are in condition for allowance and such action is earnestly solicited. If, after careful consideration of this Amendment, the Examiner maintains that there are issues which remain an impediment to allowance, he is invited to telephone the undersigned to discuss such matters in more detail.

Respectfully submitted,

Date: 8-27-04



Pamela C. Ancona, Ph.D.
Attorney for Applicants
Reg. No. 41,494

Pfizer Inc.
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-6031